Department of Bionano Technology and Gachon BioNano Research Institute, Gachon University, Gyeonggi-do, Republic of Korea.
Department of Microbiology, College of Medicine, and the Institute for Viral Diseases, Korea University, Seoul 136-705, Republic of Korea.
Eur J Pharm Biopharm. 2019 Oct;143:1-7. doi: 10.1016/j.ejpb.2019.08.005. Epub 2019 Aug 6.
During the manufacture of H1N1 microneedles, a stabilizer is usually added to maintain the antigenicity of the vaccine. However, finding a suitable stabilizer is difficult, and the addition of a stabilizer can limit the antigen dose and the addition of an adjuvant because of the limited volume of the microneedles. In this study, the authors evaluated whether H1N1 microneedles could be fabricated without a stabilizer by keeping the production environment at a low temperature. H1N1 microneedle patches without a stabilizer were prepared in a process that involved maintaining a low temperature of 10 °C. The protective immune response to this method of drug application was investigated by comparing it with traditional intramuscular (IM) immunization and with the use of H1N1 microneedles with a stabilizer. A process-sensitive antigen, H1N1, was stabilized without the use of a stabilizer in a process that maintained a low temperature of 10 °C. The preparation process consisted of coating and drying processes. In animal experiments, mice were immunized using an array of low-temperature H1N1 microneedles without a stabilizer (LT-MN), and they showed strong antibody responses. Compared to three other application methods of traditional IM immunization, low-temperature H1N1 microneedles with a stabilizer (LT-MN-T), and room-temperature H1N1 microneedles with a stabilizer (RT-MN-T), LT-MN produced comparable results in inducing protective immunity. A plaque reduction neutralization test found that LT-MN and LT-MN-T provided greater immunity compared with IM and RT-MN-T. A process in which the temperature is maintained at 10 °C can provide successful vaccination with H1N1 microneedles without the addition of a stabilizer. This process can be applied to various temperature-sensitive biologics.
在制造 H1N1 微针时,通常会添加稳定剂来维持疫苗的抗原性。然而,寻找合适的稳定剂很困难,并且由于微针的体积有限,添加稳定剂会限制抗原剂量和佐剂的添加。在这项研究中,作者通过将生产环境保持在低温下来评估是否可以在不添加稳定剂的情况下制造 H1N1 微针。在保持 10°C 低温的过程中制备了不含稳定剂的 H1N1 微针贴片。通过将其与传统的肌肉内(IM)免疫和使用含稳定剂的 H1N1 微针进行比较,研究了这种药物应用方法的保护性免疫反应。在不使用稳定剂的情况下,在保持 10°C 低温的过程中稳定了一种过程敏感抗原 H1N1。该制备工艺包括涂覆和干燥工艺。在动物实验中,使用不含稳定剂的低温 H1N1 微针阵列(LT-MN)对小鼠进行免疫,它们表现出强烈的抗体反应。与传统 IM 免疫的另外三种应用方法(低温 H1N1 微针含稳定剂(LT-MN-T)和室温 H1N1 微针含稳定剂(RT-MN-T))相比,LT-MN 在诱导保护性免疫方面产生了相当的结果。蚀斑减少中和试验发现,LT-MN 和 LT-MN-T 提供的免疫效果优于 IM 和 RT-MN-T。将温度保持在 10°C 的过程可以成功地对 H1N1 微针进行疫苗接种,而无需添加稳定剂。该过程可应用于各种对温度敏感的生物制剂。